New thread probably better ideaEdison...

New thread probably better idea

Edison report

http://www.investing.com/analysis/alchemia:-pivotal-phase-iii-result-due-in-q214-203867



a snip

"Valuation: Potentially a multiple of the current price
Alchemia believes HA-Irinotecan could generate between US$465m and US$1.5bn in annual sales (depending on the degree of PFS improvement). With mid-teen royalties, sizeable milestones and potential launch dates of H215 in the US and H116 in Europe, the upside of a successful trial outcome is significant. However, an equivocal or negative result would similarly lower the valuation materially."